Cencora (COR) insider buying and selling
Every Table I transaction reported by directors and officers of S&P 500 companies on SEC Form 4 filings (2 business days to file): each row labeled with its official transaction code, nothing filtered out beforehand.
Open-market purchases (code P) are the rare signal, in green; sales (code S) are common and often pre-scheduled (10b5-1). Table II (derivatives) is not included: its prices are exercise prices, not market values. Guide: insider buying.
| Date | Ticker | Insider | Role | Shares | Price | Amount | % of stake | Type / filing |
|---|
Download these transactions as CSV No account, no sign-up. The data is public: it comes from SEC Form 4 filings.
Cencora, Inc. (COR) insider buying and selling: 3 purchases, 16 sales
103 Form 4 Table I transactions filed with the SEC by Cencora, Inc. insiders between 2025-09-18 and 2026-10-05 (15-month history): 3 open-market purchases and 16 sales, plus 84 transactions under other Form 4 codes, broken down one by one below. The largest open-market trade is a sale of $9.1M by Collis Steven H on 2025-09-16.
Cencora insider buying and selling over the last 12 months
Between Oct 21, 2025 and Oct 20, 2026, Cencora insiders filed 3 purchases worth $2.3M and 12 sales worth $15.1M on the open market. The net balance is on the sell side: $12.7M more sold than bought.
The biggest buyer was Durcan Dermot Mark (Director): $2.2M in 2 purchases, out of 2 different buyers. The biggest seller was Mauch Robert P. (President & CEO): $7.3M in 5 sales, out of 5 different sellers.
The largest trade of the period was a sale of $3.7M on Aug 24, 2026, by Campbell Elizabeth S (Executive Vice President). Form 4 on sec.gov (0001882641-26-000008).
Of the 12 sales, 7 (58%, $7.9M) carry the 10b5-1 plan flag on the Form 4, meaning they were scheduled months ahead; the other 5 do not.
The last three months show 0 purchases and 4 sales, against 3 and 0 in the three before. The latest purchase is from Jun 22, 2026; the latest sale from Oct 1, 2026.
Against its sector (Healthcare, 59 companies with an insider page on this site), over the same dates the median is 9 sales and 0 purchases on the open market. Cencora has more sales than 38 of the other 58, ranks 34 of 59 by net dollars sold, and 19 of the 59 have at least one purchase, Cencora included.
The 20 most important trades
The 3 open-market purchases first, then the rest, each type from largest to smallest. The full history is in the tool above, already searched.
See all 103 COR trades in the full history →
| Trade date | Filed | Insider | Role | Amount | Code | Filing |
|---|---|---|---|---|---|---|
| 2026-06-18 | 2026-06-22 | Durcan Dermot Mark | Director | $1.1M | P — Open-market purchase | SEC |
| 2026-05-28 | 2026-05-28 | Durcan Dermot Mark | Director | $1.1M | P — Open-market purchase | SEC |
| 2026-06-22 | 2026-06-24 | Tyler Lauren M | Director | $149k | P — Open-market purchase | SEC |
| 2025-09-16 | 2025-09-18 | Collis Steven H | Executive Chairman | $9.1M | S — Open-market sale (scheduled 10b5-1)2 Form 4 footnotesF1 The sale of stock reflected in this Form 4 was effected pursuant to a Rule 10b5-1 plan adopted by the reporting person on 11/25/24. F2 The sale price reported in Column 4 is a weighted average price. These shares were sold in multiple tranches ranging from $287.372 to $292.625 inclusive. The reporting person undertakes to provide the Company, any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each price within the ranges set forth in the footnote. | SEC |
| 2026-08-24 | 2026-08-25 | Campbell Elizabeth S | Executive Vice President | $3.7M | S — Open-market saleForm 4 footnoteF1 The sale price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $324.06 to $324.37 inclusive. The reporting person undertakes to provide to the Company, any security holder of the Company or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each price within the ranges set forth in this footnote. | SEC |
| 2025-11-18 | 2025-11-19 | Mauch Robert P. | President & CEO | $1.9M | S — Open-market sale (scheduled 10b5-1)Form 4 footnoteF1 The sale of stock reflected in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on 11/15/24. | SEC |
| 2026-01-20 | 2026-01-22 | Mauch Robert P. | President & CEO | $1.8M | S — Open-market sale (scheduled 10b5-1) | SEC |
| 2025-12-18 | 2025-12-22 | Mauch Robert P. | President & CEO | $1.8M | S — Open-market sale (scheduled 10b5-1) | SEC |
| 2025-10-20 | 2025-10-21 | Mauch Robert P. | President & CEO | $1.7M | S — Open-market sale (scheduled 10b5-1)Form 4 footnoteF1 The sale of stock reflected in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on 11/15/24. | SEC |
| 2025-09-18 | 2025-09-22 | Mauch Robert P. | President & CEO | $1.5M | S — Open-market sale (scheduled 10b5-1)Form 4 footnoteF1 The sale of stock reflected in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on 11/15/24. | SEC |
| 2025-12-17 | 2025-12-19 | Krikorian Lazarus | SVP & Chief Accounting Officer | $1.4M | S — Open-market sale | SEC |
| 2026-02-20 | 2026-02-24 | Mauch Robert P. | President & CEO | $1.4M | S — Open-market sale (scheduled 10b5-1) | SEC |
| 2025-12-19 | 2025-12-22 | Campbell Elizabeth S | Executive Vice President | $1.1M | S — Open-market sale | SEC |
| 2025-10-01 | 2025-10-03 | Campbell Elizabeth S | Executive Vice President | $591k | S — Open-market sale (scheduled 10b5-1)Form 4 footnoteF1 The sale of stock reflected in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on 12/20/2024. | SEC |
| 2025-12-19 | 2025-12-22 | Battaglia Silvana | Executive Vice President | $579k | S — Open-market sale | SEC |
| 2026-02-18 | 2026-02-20 | Mauch Robert P. | President & CEO | $479k | S — Open-market sale (scheduled 10b5-1) | SEC |
| 2026-09-16 | 2026-09-17 | Greenberg Lon R | Director | $411k | S — Open-market sale | SEC |
| 2026-09-01 | 2026-09-02 | Krikorian Lazarus | SVP & Chief Accounting Officer | $321k | S — Open-market sale (scheduled 10b5-1)Form 4 footnoteF1 The sale of stock reflected in this Form 4 was effected pursuant to a Rule 10b5-1 plan adopted by the reporting person on 06/03/2026. | SEC |
| 2026-10-01 | 2026-10-05 | Krikorian Lazarus | SVP & Chief Accounting Officer | $299k | S — Open-market sale (scheduled 10b5-1) | SEC |
| 2025-12-17 | 2025-12-19 | Cleary James F | Chief Financial Officer | $9.3M | F — Tax withholding (shares surrendered for taxes)Form 4 footnoteF1 Satisfaction of tax withholding obligation incident to the exercise of stock options. | SEC |
The period balance: money in, money out
Across the Form 4 filings submitted between Sep 18, 2025 and Oct 5, 2026, Cencora, Inc. open-market activity adds up to 3 purchases worth $2.3M and 16 sales worth $27.9M. The net balance is $25.6M on the sell side.
Only codes P and S count, where an insider puts in or takes out their own money. A selling balance like Cencora, Inc.'s is the norm in the S&P 500, where much of the pay comes as stock. It is not a recommendation to buy or sell: it is what was filed.
Every transaction, code by code
| Code | What it means | Trades | Reported amount |
|---|---|---|---|
| A | Grant or award | 32 | $2.6M |
| M | Option exercise | 26 | $11.2M |
| F | Tax withholding (shares surrendered for taxes) | 24 | $36.6M |
| S | Open-market sale | 16 | $27.9M |
| P | Open-market purchase | 3 | $2.3M |
| G | Gift | 2 | $0 |
| Total | Everything filed in the period | 103 | $80.6M |
25 of the 103 rows carry no usable amount on the Form 4: they count as trades and add $0. The code labels come from the SEC index.
Who has traded
Over the 15 months of history, 18 distinct people or entities have filed Cencora, Inc. transactions: 2 bought on the open market and 6 sold. Counted by CIK, the fixed number the SEC gives each filer, and not by name, which each filer types their own way.
Of the 6 who sold on the open market (16 sales in all), the three biggest sellers account for $24.9M of the $27.9M: 89% of the money in three people.
| Filer | Role | Transactions | Bought (count) | Sold (count) | Last filed |
|---|---|---|---|---|---|
| Mauch Robert P. | President & CEO | 22 | — | $10.4M (7) | 2026-02-24 |
| Collis Steven H | Executive Chairman | 2 | — | $9.1M (1) | 2025-09-18 |
| Campbell Elizabeth S | Executive Vice President | 13 | — | $5.4M (3) | 2026-08-25 |
| Durcan Dermot Mark | Director | 3 | $2.2M (2) | — | 2026-06-22 |
| Krikorian Lazarus | SVP & Chief Accounting Officer | 11 | — | $2.0M (3) | 2026-10-05 |
| Battaglia Silvana | Executive Vice President | 11 | — | $579k (1) | 2026-07-07 |
| Greenberg Lon R | Director | 2 | — | $411k (1) | 2026-09-17 |
| Tyler Lauren M | Director | 6 | $149k (1) | — | 2026-08-04 |
Shown here are the 8 who moved the most money, out of 18. The rest are in the full history, one link above. The name links to all their trades, in any company. "Transactions" counts any code; the money, open market only. Role: from their latest filing.
Month by month
By the month the trade was executed, not the month it was filed; months with no trades show zero. The busiest month was Dec 2025: 0 purchases and 4 sales, worth $4.9M. 4 of the 15 months have none.
| Month | Purchases | Amount | Sales | Amount |
|---|---|---|---|---|
| Aug 2025 | 0 | $0 | 0 | $0 |
| Sep 2025 | 0 | $0 | 2 | $10.6M |
| Oct 2025 | 0 | $0 | 2 | $2.3M |
| Nov 2025 | 0 | $0 | 1 | $1.9M |
| Dec 2025 | 0 | $0 | 4 | $4.9M |
| Jan 2026 | 0 | $0 | 1 | $1.8M |
| Feb 2026 | 0 | $0 | 2 | $1.8M |
| Mar 2026 | 0 | $0 | 0 | $0 |
| Apr 2026 | 0 | $0 | 0 | $0 |
| May 2026 | 1 | $1.1M | 0 | $0 |
| Jun 2026 | 2 | $1.2M | 0 | $0 |
| Jul 2026 | 0 | $0 | 0 | $0 |
| Aug 2026 | 0 | $0 | 1 | $3.7M |
| Sep 2026 | 0 | $0 | 2 | $732k |
| Oct 2026 | 0 | $0 | 1 | $299k |
The last month may be partial: a Form 4 is filed up to two business days later. The table does not say whether the pattern is good or bad; it says when it happened.
Cencora, Inc. (COR) analysis page →
Other Healthcare companies with insider trades
All 500 are listed in the section index →
Which insiders are buying their own company stock →
How to read this data
11 of the 16 sales in the table are flagged as scheduled (10b5-1 plan): signed months ahead and executed automatically, so they say nothing about what the insider thinks today. Cencora's 3 open-market purchases (code P) are the rare signal: insiders are already paid in stock, so buying more means putting in their own money. The latest filing is from Oct 5, 2026, and a Form 4 arrives up to two business days after the trade.
8 of the 20 rows in the table carry footnotes from the Form 4 itself, folded into the code column and copied verbatim; a row with no footnote means the filing has none.
Guide: Insider buying · all guides
What is behind these trades
The concepts on this page, explained from scratch in the Academy. Free, no account.
- What the efficiency hypothesis says and what it does NOT sayIf an insider's purchase is public and anyone can read it, is there any information left in it? That is the exact question that brings people here.
- Who really moves the market: the types of investorWho sits on the other side of each order, and where a company's own insiders fit among them.
- Supply, demand and price: why it rises and falls constantlyHow a piece of news ends up inside the price, and why the reaction to a filed sale is rarely the one you would expect.
Source: SEC EDGAR Form 4. This is a list of public facts, not financial advice or a recommendation to buy or sell.